Skip to content

Screening and Secondary Prevention Rheumatic Heart Disease Study

Screening and Secondary Prevention Rheumatic Heart Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05991219
Acronym
S2-RHD
Enrollment
5000
Registered
2023-08-14
Start date
2022-09-26
Completion date
2028-12-31
Last updated
2023-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic Heart Disease

Brief summary

After basic clinical screening including history and physical, Point of care ultrasound will be performed to look at Mitral, Aortic and Tricuspid Valves for regurgitation or stenosis. For patients with confirmed Rheumatic heart disease (RHD), treatment and referral depending on stage of disease. Antibiotic prescription could be shifted to community health workers delivering preventive medications via practical clinical algorithms, diagnostic tools, availability of appropriate antibiotics, and supportive supervision. Patients will have repeat imaging at 2 years and 5 years to look at the outcome of delayed progression of valve disease.

Detailed description

Screening for RHD should be carried out since it is a major health concern that has been shown to have a treatable and detectable latent stage that can be diagnosed using a simple sensitive test (point of care ultrasound) and early treatment (secondary prevention using antibiotic prophylaxis) can provide a better outcome (slow progression of disease) in a cost effective way. The investigators aim to study the Incidence and Prevalence of RHD in community and school settings and aim to intervene depending on the stage the disease is picked up in.

Interventions

None listed

Sponsors

National Institute of Cardiovascular Diseases, Pakistan
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
10 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Rural communities in Sindh

Exclusion criteria

* Refused to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Rheumatic heart diseaseAt the time of screening echocardiogramNumber of patients

Countries

Pakistan

Contacts

Primary ContactSabha Bhatti, MD
drsabhabhatti@gmail.com+92 335 5554346

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026